China Approves Launch of 7th Domestic Vaccine 'Kewayfu'

Inactivated Vaccine

[Image source=AP Yonhap News]

[Asia Economy Reporter Cho Hyun-ui] China has approved the release of its seventh domestically developed COVID-19 vaccine.

On the 10th, according to the English edition of the state-run Global Times by China’s official newspaper Huanqiu Shibao, the Institute of Medical Biology at the Chinese Academy of Medical Sciences located in Kunming, Yunnan Province, launched its self-developed COVID-19 vaccine "Kewaifu" the day before.

This vaccine requires two doses, similar to the Pfizer and AstraZeneca vaccines, with an interval of 2 to 4 weeks between doses.

Kewaifu is an inactivated vaccine that introduces dead virus particles into the body to generate antibodies. Among the vaccines approved by Chinese authorities, five types including Sinovac and Sinopharm use the inactivated method.

The Chinese government plans to produce 500 million to 1 billion doses of Kewaifu annually. Tao Lina, a Chinese vaccine expert, evaluated that "Kewaifu will raise China’s inactivated vaccine production capacity to 6 billion doses per year."

This content was produced with the assistance of AI translation services.